Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. The world's oil supply is ...

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

“Pfizer beat the numbers and people just yawned. Oh my god the group is so challenged. “But we’re looking for that big win ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...

Drugmaker Pfizer ($PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $26.5 for Pfizer over the last 3 months.

Investing.com -- Metsera Inc (NASDAQ:MTSR) stock rose 13% Tuesday as pharmaceutical giants Novo Nordisk (NYSE:NVO) and Pfizer ...

Currently, the analyst consensus on Pfizer is a Hold with an average price target of $28.60, representing a 15.98% upside. In a report released today, J.P. Morgan also maintained a Hold rating on the ...